Advanced Solid Malignancies
Conditions
Brief summary
This is a Phase I, open-label study to assess the safety, tolerability, pharmacokinetics and anti-tumor activity of AZD4635 in Japanese patients with advanced solid malignancies. This study consists of 2 cohorts, Cohort1 and Cohort2. At least 3 or up to 6 evaluable Japanese patients with advanced solid malignancies will be enrolled in Cohort1 and 6 evaluable patients will be enrolled in Cohort2.
Detailed description
Objectives: Primary objective: Investigate the safety and tolerability of AZD4635 monotherapy in Japanese patients Secondary objective: Characterize the single-dose and multiple-dose plasma pharmacokinetic (PK) parameters of AZD4635 monotherapy Determine the preliminary anti-tumor activity of AZD4645 monotherapy Overall design: This is a phase I, open-label study of AZD4635 in Japanese patients with advanced solid malignancies. The study consists of 2 cohorts, Cohort 1 and Cohort 2. At least 3 or up to 6 evaluable Japanese subjects with advanced solid malignancies will be enrolled in Cohort 1 and 6 evaluable patients will be required for Cohort 2 to confirm the tolerability. The total number of evaluable subjects in each cohort will depend upon available data in each cohort and decision of Safety Review Committee(SRC). Study Period: The study is expected to start in June 2019 and end in June 2020. Number of Subjects: 9 to 12 evaluable subjects will be enrolled in this study to confirm the tolerability. Treatments and treatment duration: Subjects will receive AZD4635 once daily (QD). A single dose of AZD4635 will be taken on Cycle 0 Day1 and the subsequent dose of AZD4635 will be taken from Cycle 1 Day 1 until discontinuation criterion is met. A cycle of study treatment will be defined as 21 days of continuous dosing.
Interventions
DRUGAZD4635
AZD4635 taken orally
Sponsors
AstraZeneca
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 130 Years
Healthy volunteers
No
Inclusion criteria
Major Inclusion Criteria: * Adult subjects; age ≥ 20 years * Histologically or cytological confirmation of a solid, malignant tumor, excluding central nervous system (CNS) tumors and lymphoma, that is refractory to standard therapy or for which no standard of care regimen currently exists * Patients must have either at least one lesion that can be evaluable using RECIST v1.1 or patients with mCRPC must have measurable prostate specific antigen above normal limits (per local ranges) * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Normotensive or well controlled blood pressure, with or without current antihypertensive treatment * Females of child-bearing potential must use 2 highly effective methods of contraception * Male patients should be willing to use barrier contraception Major
Exclusion criteria
* Any investigational medicinal product or other systemic anticancer treatment within at least 4 weeks prior to the first dose of study treatment, or within 8 weeks after immunotherapy or other long half-life antibody therapy, whichever is the most appropriate and as judged by the Investigator. * Evidence of recent or significant cardiovascular disease * Unresolved toxicities from prior therapy greater than CTCAE Grade 1 at starting study treatment * History of seizures, CNS tumors or CNS metastasis * Active or prior documented autoimmune or inflammatory disorders within the past 3 years to the start of treatment * Patients with prior ≥ Grade3 immune-mediated reactions * Evidence of severe or uncontrolled systemic diseases * Inadequate bone marrow reserve or organ function * Refractory nausea and vomiting, chronic gastrointestinal diseases, or previous significant bowel resection that would preclude adequate absorption of AZD4635 * History of hypersensitivity to AZD4635 or drugs with a similar chemical structure or class to AZD4635 * Judgment by the Investigator that the patient should not participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of Adverse event and SAE | From the informed consent to 30 days post last dose | Investigate the safety and tolerability of AZD4635 |
| The incidence of Dose-limiting toxicity (DLTs) | 25 days (Cycle0 and Cycle1) | Investigate the safety and tolerability of AZD4635 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) | Tumor assessment is Cycle 4 Day 1 and then on Day 1 of each even numbered cycle (+/-5 days) until disease progression. Expected to be for up to 6 months. | Summarize based on RECIST 1.1 by cohort and overall. |
| Maximum plasma concentration (Cmax) | Samples will be collected at pre-specified time points in the single-dose and multiple-dose portion of the study beginning with Cycle 1 Day 1 until last dose. Expected to be for up to 6 months. | Characterize the single-dose and multiple-dose plasma of AZD4635 |
| Disease control rate (DCR) | Tumor assessment is Cycle 4 Day 1 and then on Day 1 of each even numbered cycle (+/-5 days) until disease progression. Expected to be for up to 6 months. | Summarize based on RECIST 1.1 by cohort and overall. |
| Area under the plasma concentration-time curve (AUC) | Samples will be collected at pre-specified time points in the single-dose and multiple-dose portion of the study beginning with Cycle 1 Day 1 until last dose. Expected to be for up to 6 months. | Characterize the single-dose and multiple-dose plasma of AZD4635 |
Countries
Japan
Outcome results
None listed